Cullinan Therapeutics, Inc. CGEM Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s operating income?
- Cullinan Therapeutics, Inc. (CGEM) reported operating income of -$53.7M in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s operating income changed year-over-year?
- Cullinan Therapeutics, Inc.'s operating income increased by 2.4% year-over-year, from -$55M to -$53.7M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s operating income?
- Over 3 years (2021 to 2025), Cullinan Therapeutics, Inc.'s operating income has grown at a 52.6% compound annual growth rate (CAGR), from -$67.95M to -$241.65M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.